Huashan Hospital

Running trials

• Not yet recruiting

  Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis

  NCT07277218· Chunshui He· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Clinical Trial of GenSci136 in Patients With Myasthenia Gravis

  NCT07936084· Phase 1/2· Changchun GeneScience Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo

  NCT07840820· Phase 2/3· Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.· Source

• Recruiting

  Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study

  NCT07923812· Fudan University· Source

• Recruiting

  Sonrotoclax Plus Azacitidine in Patients With MDS-IB2

  NCT07885397· Phase 1/2· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Not yet recruiting

  Early Anticoagulation Therapy After Endovascular Treatment for Acute Ischemic Stroke With Atrial Fibrillation

  NCT07849777· The Fourth Affiliated Hospital of Soochow University· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Not yet recruiting

  An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis

  NCT07818291· Phase 1· Shanghai Lanyi Therapeutics Co., Ltd.· Source

• Recruiting

  Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis

  NCT07800104· Phase 1· QuantX Biosciences US Inc.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

  NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Cohort Study on the Integrated Management of Chronic Kidney Disease

  NCT07712341· Huashan Hospital· Source

• Not yet recruiting

  PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke

  NCT07466251· Phase 4· Peking Union Medical College Hospital· Source

• Recruiting

  A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

  NCT07622342· Phase 2· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Recruiting

  ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  NCT07741461· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome

  NCT07894107· Beijing Tiantan Hospital· Source

• Recruiting

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  NCT07733765· Phase 3· Pfizer· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

  NCT07600788· Phase 1· Ausper Biopharma Co., Ltd.· Source

• Recruiting

  BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children

  NCT07893444· Phase 2· Huashan Hospital· Source

• Recruiting

  A Clinical Study of a Fully Implanted, Wireless and Functional BCI for Upper-Limb Functional Replacement in Tetraplegia Due to Spinal Cord Injury: Efficacy and Safety

  NCT07720882· NeuroXess Technology (shanghai) Co.,Ltd.· Source

• Not yet recruiting

  Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL

  NCT07692399· Phase 2· Huashan Hospital· Source

• Recruiting

  A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

  NCT07604116· Phase 1· Synusight Biotech (Shanghai) Co., Ltd.· Source

• Recruiting

  Study of D-2570 in Subjects With Non-Segmental Vitiligo

  NCT07625891· Phase 2· InventisBio Co., Ltd· Source

• Recruiting

  A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer

  NCT07707531· Early phase 1· Huashan Hospital· Source

• Recruiting

  A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)

  NCT07513441· Phase 1· H. Lundbeck A/S· Source

• Recruiting

  A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke

  NCT06459427· Yanbing Yu· Source

• Recruiting

  A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

  NCT07693738· Phase 1· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Recruiting

  Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

  NCT07310433· Phase 2· Yung NA· Source

• Recruiting

  Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

  NCT07571161· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Implantable Wireless Brain-Machine Interface System for Spinal Cord Injury: Efficacy and Safety Study

  NCT07603752· Shanghai StairMed Technology Co., Ltd.· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

  NCT07554222· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

  NCT07493265· Phase 2· Eisai Inc.· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

  NCT07362355· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  NCT07244263· Phase 2· Takeda· Source

• Recruiting

  A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

  NCT07297212· Phase 2· BioNTech SE· Source

• Recruiting

  Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

  NCT07381738· Phase 2· Fudan University· Source

• Recruiting

  Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

  NCT07360808· Cytori Therapeutics· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

  NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source

• Recruiting

  TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria

  NCT07268131· Fudan University· Source

• Recruiting

  A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

  NCT07250802· Phase 3· Takeda· Source

Showing 50 of 153.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke10 recruiting
• Myasthenia gravis9 recruiting
• Hepatitis B8 recruiting
• Gastric and oesophageal cancer7 recruiting
• Alzheimer disease6 recruiting
• Atopic dermatitis (eczema)6 recruiting
• Chronic kidney disease5 recruiting
• Pancreatic cancer5 recruiting
• Parkinson disease5 recruiting
• Tuberculosis5 recruiting
• Alopecia areata4 recruiting
• Vitiligo4 recruiting
• Childhood cancers3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Migraine3 recruiting
• Psoriasis3 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Glioblastoma2 recruiting
• Gout2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Liver cirrhosis2 recruiting
• Lupus (SLE)2 recruiting
• Peripheral artery disease2 recruiting
• Prostate cancer2 recruiting
• Spinal cord injury2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Brain aneurysm1 recruiting
• Crohn's disease1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple system atrophy1 recruiting
• Myelodysplastic syndromes1 recruiting
• Narcolepsy1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

  NCT07145229· Phase 2· Atom Therapeutics Co., Ltd· Source

• Terminated

  A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

  NCT07100938· Phase 2· BeiGene· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Trial of Rehabilitation Paired With VNS for Motor Function in Patients With Stroke (Repair Study)

  NCT06722677· Beijing Pins Medical Co., Ltd· Source

• Completed

  Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

  NCT06398652· Phase 3· Taizhou Mabtech Pharmaceutical Co.,Ltd· Source

• Completed

  A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis

  NCT07051538· Phase 1· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Terminated

  TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

  NCT06106841· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  BLAZE-Limiting Approach in NMOSD

  NCT06888622· Huashan Hospital· Source

• Completed

  A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT06012812· Phase 2· Shanghai Hengrui Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of Daridorexant in Chinese Patients With Insomnia Disorder

  NCT06010693· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Completed

  Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

  NCT05959083· AbbVie· Source

• Completed

  A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

  NCT05996848· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

  NCT06103825· Phase 3· Ignis Therapeutics (Suzhou) Limited· Source

• Completed

  A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

  NCT05658484· Phase 4· Biogen· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Completed

  A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

  NCT05810948· Phase 2· argenx· Source

• Completed

  rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

  NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Completed

  A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma

  NCT07497373· Phase 1· Jecho Biopharmaceuticals Co., Ltd.· Source

• Completed

  Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients

  NCT05490836· Huashan Hospital· Source

• Completed

  Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

  NCT05439629· Phase 3· Bio-Thera Solutions· Source

• Completed

  Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

  NCT05332210· Phase 3· Harbour BioMed (Guangzhou) Co. Ltd.· Source

• Completed

  Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout

  NCT07752810· Phase 1/2· Hangzhou Grand Biologic Pharmaceutical, Inc.· Source

• Completed

  The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

  NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

  NCT05029921· Phase 4· Janssen Research & Development, LLC· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

  NCT05004350· Phase 2· Pierre Fabre Medicament· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy

  NCT07563634· Phase 3· Jiangxi Qingfeng Pharmaceutical Co. Ltd.· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

  NCT04805307· Phase 1· Keymed Biosciences Co.Ltd· Source

• Completed

  A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

  NCT04535544· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms

  NCT04289480· Medos International SARL· Source

• Completed

  A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

  NCT04451772· Phase 2· AbbVie· Source

• Completed

  A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  NCT04225715· Phase 2· Hoffmann-La Roche· Source

• Completed

  Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

  NCT04431895· Early phase 1· Huashan Hospital· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke162 works · 13 trials
• Alzheimer disease114 works · 9 trials
• Parkinson disease60 works · 6 trials
• Glioblastoma38 works · 3 trials
• Psoriasis34 works · 13 trials
• Atopic dermatitis (eczema)30 works · 14 trials
• Myasthenia gravis26 works · 15 trials
• Vitiligo24 works · 8 trials
• Osteoporosis21 works · 0 trials
• Spinal cord injury21 works · 2 trials
• Hepatitis B18 works · 11 trials
• Alopecia areata17 works · 7 trials
• Brain aneurysm14 works · 2 trials
• Systemic sclerosis (scleroderma)11 works · 3 trials
• Neuromyelitis optica (NMOSD)10 works · 2 trials
• Gout10 works · 4 trials
• Meningioma9 works · 0 trials
• Ankylosing spondylitis8 works · 1 trial
• Multiple system atrophy8 works · 1 trial
• Liver cirrhosis6 works · 2 trials
• IgA nephropathy5 works · 2 trials
• Vascular dementia5 works · 0 trials
• Spinal muscular atrophy5 works · 1 trial
• Sjögren's disease4 works · 0 trials
• Pompe disease3 works · 0 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 works · 1 trial